Stomach Ulcers: PFAS and the Treatment of Stomach Ulcers- Toxicological, Clinical, and Policy Perspectives
Abstract
Per- and polyfluoroalkyl substances (PFAS) are persistent synthetic chemicals with widespread environmental and human exposure. Their bioaccumulative and toxic properties have raised growing concern for human health, particularly in gastrointestinal disorders such as stomach ulcers. This paper explores the mechanisms by which PFAS influence the development and treatment of stomach ulcers, focusing on their interactions with gut microbiota, oxidative stress pathways, and ulcer medications. It further examines clinical and policy implications, emphasizing the need for integrated environmental and medical strategies to mitigate PFAS-associated gastrointestinal risks.
1. Introduction
Stomach ulcers, also known as peptic ulcers, are erosions of the gastric or duodenal mucosa caused primarily by Helicobacter pylori infection and the chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) (Malfertheiner et al., 2017). Standard therapy includes antibiotics, proton pump inhibitors (PPIs), and mucosal protective agents. However, environmental exposures—particularly to persistent organic pollutants like PFAS—have emerged as modifiers of gastrointestinal physiology and drug response (Sunderland et al., 2019).
PFAS are a class of over 12,000 fluorinated compounds used in industrial and consumer applications, such as non-stick cookware, textiles, firefighting foams, and food packaging (Kwiatkowski et al., 2020). Because of their strong carbon–fluorine bonds, PFAS resist environmental degradation and accumulate in human tissues. Growing evidence indicates that PFAS exposure can disrupt endocrine balance, alter gut microbiota, and interfere with metabolic pathways—factors that may influence both the development and treatment of stomach ulcers (Grandjean & Clapp, 2015).
2. PFAS Exposure Pathways and Gastrointestinal Accumulation
PFAS enter the human body primarily through contaminated drinking water, food, and household dust (Sunderland et al., 2019). Once absorbed, they bind to plasma proteins and concentrate in the liver, kidneys, and intestinal mucosa. Research indicates that PFAS accumulation in the gut epithelium alters epithelial permeability and modulates inflammatory signaling (DeWitt, 2015).
Chronic low-level exposure to compounds such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) may lead to long-term gastrointestinal disturbances. PFAS have been detected in gastric mucosa samples from individuals residing in high-contamination regions, suggesting a direct exposure route affecting the gastric environment (Zheng et al., 2023).
3. Mechanisms of PFAS Interference with Stomach Ulcer Pathophysiology
3.1 Disruption of Gut Microbiota
The gut microbiome plays a vital role in maintaining gastric integrity and modulating inflammatory responses. PFAS exposure induces gut dysbiosis, reducing beneficial bacteria such as Lactobacillus and Bifidobacterium while increasing pro-inflammatory taxa (Zhang et al., 2020). This imbalance weakens mucosal defenses and interferes with drug metabolism, particularly antibiotics used to eradicate H. pylori. Dysbiosis has also been associated with increased intestinal permeability, allowing gastric acid and inflammatory mediators to damage the mucosal lining (Choi et al., 2022).
3.2 Induction of Oxidative Stress and Inflammation
PFAS exposure promotes reactive oxygen species (ROS) formation and activates inflammatory transcription factors such as NF-κB (Quinete et al., 2022). The resulting oxidative stress damages epithelial DNA and lipids, thereby exacerbating mucosal injury. Elevated inflammatory cytokines (IL-6, TNF-α) have been reported in PFAS-exposed populations (Corsini et al., 2014), creating an environment unfavorable for ulcer healing. Chronic inflammation of the gastric mucosa may also elevate long-term risks of gastric metaplasia and cancer (Zheng et al., 2023).
3.3 Endocrine and Hormonal Dysregulation
PFAS disrupt thyroid hormone homeostasis, glucocorticoid activity, and other endocrine pathways (Kato et al., 2021). These hormonal imbalances can affect gastric acid secretion and impair mucosal regeneration, reducing the effectiveness of ulcer therapy. Moreover, hormonal dysregulation may alter stress responses that exacerbate peptic ulcer disease progression (Lau et al., 2018).
4. Pharmacological Interactions Between PFAS and Ulcer Medications
The therapeutic management of peptic ulcers depends heavily on drug efficacy and metabolism. PFAS can interfere with the cytochrome P450 (CYP) enzyme system, which metabolizes PPIs and other drugs (Anselmo et al., 2021). This interference may reduce drug clearance or potency.
| Drug Category | PFAS Interaction Mechanism | Therapeutic Impact |
|---|---|---|
| Proton Pump Inhibitors (PPIs) | Compete for CYP2C19 and CYP3A4 metabolism | Reduced efficacy or altered plasma levels |
| Antibiotics (e.g., Clarithromycin, Amoxicillin) | Gut microbiome disruption | Decreased H. pylori eradication rate |
| Antacids and Sucralfate | PFAS affects mucosal binding and ion exchange | Diminished protective coating |
| Bismuth compounds | PFAS-metal interactions reduce bioavailability | Lower therapeutic activity |
Such pharmacokinetic disruptions can prolong ulcer healing, necessitating higher doses or alternative therapies.
5. Epidemiological and Experimental Evidence
While human data remain limited, epidemiological studies from PFAS-contaminated regions—such as the Mid-Ohio Valley in the United States—have reported increased gastrointestinal morbidity and dyspeptic symptoms (Steenland et al., 2020). Experimental studies in rodents confirm that chronic PFAS exposure leads to gastric epithelial thinning, impaired mucosal regeneration, and acid imbalance (Liu et al., 2022).
Furthermore, biomonitoring research indicates that individuals with elevated serum PFAS concentrations exhibit higher inflammatory markers and altered liver and gastric enzyme profiles (Zheng et al., 2023). These findings underscore PFAS’s potential to complicate both ulcer etiology and treatment outcomes.
6. Policy and Public Health Implications
6.1 Integrating PFAS Exposure Assessment into Gastroenterology
Gastroenterology clinics should incorporate PFAS exposure history—through questionnaires or biomonitoring—into the assessment of recurrent or treatment-resistant ulcers. Understanding patients’ exposure levels could guide individualized therapeutic decisions and help identify populations at environmental risk.
6.2 Strengthening Environmental Regulations
Effective PFAS regulation is critical for long-term gastric health protection. The World Health Organization (WHO, 2023) and the U.S. Environmental Protection Agency (EPA, 2023) have recently proposed limits for PFOS and PFOA in drinking water at 4 parts per trillion. Such standards should be universally adopted and localized to safeguard communities in Africa and other developing regions where monitoring is limited.
6.3 Encouraging Pharmaceutical Research
Further research is warranted to clarify PFAS–drug interactions and to develop pharmaceutical agents resilient to PFAS interference. Clinical pharmacology should expand into environmental toxicology domains to design effective therapies for populations under chronic exposure.
6.4 Enhancing Community Awareness
Public health education should emphasize practical steps to reduce PFAS intake—such as avoiding non-stick cookware, limiting packaged foods, and advocating for safe water filtration. Education is particularly critical for women, children, and patients with chronic gastrointestinal conditions, who face increased vulnerability.
7. Conclusion
The intersection between PFAS exposure and the treatment of stomach ulcers exemplifies a broader environmental-health nexus. By disturbing gut microbiota, inducing oxidative stress, and altering drug metabolism, PFAS can impede mucosal healing and compromise therapeutic outcomes. Addressing this emerging challenge demands a multidisciplinary response that integrates clinical vigilance, environmental surveillance, and robust regulatory action. Protecting gastrointestinal health in the age of persistent pollutants requires unified policies linking environmental science, medicine, and public health governance.
Comments
Post a Comment